GENE ONLINE|News &
Opinion
Blog

2020-03-24| COVID-19

Gilead’s Remdesivir Wins FDA’s Orphan Drug Designation for COVID-19 Treatment

by Ruchi Jhonsa
Share To

By Ruchi Jhonsa, Ph.D.

While the clinical trials of this promising drug against SARS-CoV-2 are still on, the FDA has provided a significant advantage to Gilead’s remdesivir today. In an announcement made this evening by the U.S. Food and Drug Administration, the agency has granted orphan drug designation to this promising experimental antiviral, a drug touted by the Trump government for COVID-19 treatment. This designation will grant Gilead Sciences, tax incentives as well as seven years of market exclusivity for drug production.

Remdesivir was already provided to patients with a severe infection on a compassionate use basis but ‘overwhelming demand’ in the past weeks forced the company to temporarily suspend drug access. This was after the news circulated about the recovery of the first coronavirus patient who happened to be under remdesivir treatment. Solid evidence from clinical trials in the coming months will tell us whether remdesivir could actually live up to its hype.

References
  1. https://www.reuters.com/article/us-health-coronavirus-gilead-sciences/gileads-potential-coronavirus-treatment-gets-fdas-orphan-drug-label-idUSKBN21A3PR
  2. https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=739020
  3. https://www.gilead.com/news-and-press/company-statements/gilead-sciences-statement-on-access-to-remdesivir-outside-of-clinical-trials

 

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
World Vaccine Congress Washington 2025 Recap: Urgent Calls for Trust, Tech, and Global Access
2025-04-25
Dupixent Makes History with FDA Approval as First New CSU Treatment in Over a Decade
2025-04-20
Fake Ozempic Floods Market as FDA Warns Patients to Check Authenticity of Prescriptions
2025-04-16
LATEST
AACR Annual Meeting 2025: Cancer Research Innovations, NIH Funding Advocacy, and AI-Driven Advances
2025-04-28
Senti Biosciences to Showcase New Cell & GeneTherapy Data at AACR Annual Meeting 2025
2025-04-27
World Vaccine Congress Washington 2025 Recap: Urgent Calls for Trust, Tech, and Global Access
2025-04-25
Astellas’ Transformation Journey: From Merger to Global Player, Betting on the Edge of Innovation and Risk?
2025-04-25
Roche Announces Massive 50 Billion Dollar Investment in the United States
2025-04-25
Steminent Stands Ready to Showcase Novel MSC-based Therapy for Spinocerebellar Ataxia at Global Stage
2025-04-24
Arkansas Medicaid Work Requirements Led to Coverage Loss for a Significant Number of Recipients
2025-04-24
EVENT
2025-04-25
AACR Annual Meeting 2025
Chicago, U.S.A
2025-05-03
29th Taiwan Joint Cancer Conference 2025
Taipei, Taiwan
2025-05-05
Swiss Biotech Day 2025
Basel, Switzerland
2025-05-13
ASGCT 28th Annual Meeting 2025
New Orleans, U.S.A.
2025-05-30
ASCO Annual Meeting 2025
Chicago, U.S.A
2025-06-11
ISSCR 2025 Annual Meeting
Hong Kong
Scroll to Top